iPSC Gene Editing
Service Details
Service Types | Gene Knockout iPS Cells/Gene Point Mutation iPS Cells/Gene Overexpression iPS Cells/Gene Interference iPS Cells/CRISPR Library Screening Related to iPS Cells |
---|---|
Timeline/Price | Consult online for details |
iPSC In Vitro Disease Modeling Research Pathway
Gene-Edited iPS Cell Models
Service Types
1 | Gene Knockout iPS Cells |
---|---|
2 | Gene Point Mutation iPS Cells |
3 | Gene Knock-in iPS Cells |
4 | Gene Overexpression iPS Cells |
5 | CRISPR Library Screening for iPS Cells |
Service Advantages
Extensive Experience in Stem Cell Cultivation
Advanced Gene Editing Platform
Designing target gene editing iPS cell models based on experimental needs.
Service Workflow
Advantage and Characteristic
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
Genetic Reference Book
iPSC-derived macrophages as effective models for studying viral biology
This study assesses whether human iPSC-derived macrophages serve as effective models for studying viral biology. The findings show that these iPSC-derived macrophages support the replication of HIV-1, dengue, and influenza viruses, with replication dynamics and phenotypes comparable to traditional blood monocyte-derived macrophages. Flow cytometry, RNA sequencing, and chromatin accessibility analyses showed that iPSC-derived macrophages closely resemble human blood monocyte-derived macrophages in surface markers and gene expression characteristics. Additionally, iPSC lines generated from chimpanzee fibroblasts exhibited different susceptibilities to dengue virus, providing a valuable resource for studying viral host tropism. The study also found that both blood-derived and iPSC-derived macrophages could restrict viral replication in the late stage of the influenza virus lifecycle. Overall, iPSC-derived macrophages have proven to be a suitable alternative to blood monocyte-derived macrophages for studying viral biology.
iPSC-derived lung and lung cancer organoid model for testing drug delivery efficacy
Lung cancer remains the leading cause of cancer-related mortality worldwide. Despite advancements in targeted therapies, drug resistance and systemic toxicity are persistent issues. This study investigates the feasibility of using patient-specific lung cancer and normal lung tissue organoid models, as well as autologous induced pluripotent stem cell (iPSC)-derived mesenchymal stromal cell (MSC)-isolated extracellular vesicles (EVs) in personalized medicine. Healthy fibroblasts were reprogrammed into iPSCs, which differentiated into branching lung organoids (BLO) and patient-matched lung cancer organoids (LCO). EVs were isolated from iPSC-MSCs and loaded with 0.07 µg/mL cisplatin, applied to both organoid models, and cytotoxicity was recorded through LDH and CCK8 assays. The results showed that fibroblast-derived iPSCs exhibited a normal karyotype and pluripotency, while iPSC-derived BLOs and LCOs expressed lung markers. Cisplatin-loaded iPSC-MSC-derived EVs caused no cytotoxicity in either organoid model, whereas 20 µg/mL cisplatin was cytotoxic to LCOs. This study presents an initial validation method for using autologous or allogeneic iPSC-MSC EVs as a testing platform for lung cancer drug delivery.
Four key factors, Oct4, Sox2, Klf4, and c-Myc, can induce cell reprogramming into iPSCs
This article discusses the technology of converting mature fibroblasts into pluripotent stem cells through specific transcription factors. The study utilized four key transcription factors—Oct4, Sox2, Klf4, and c-Myc—introduced into mouse embryonic and adult fibroblasts. Through the action of these factors, the cells gradually acquired pluripotent characteristics, exhibiting morphology and gene expression patterns similar to embryonic stem cells. The study found that the reprogrammed iPSCs could not only be maintained long-term in vitro but also differentiate into various cell types, including neural cells and cardiomyocytes, indicating that these iPSCs have favorable biological characteristics and potential applications. This study validates the effectiveness of these four transcription factors and provides new tools for future stem cell research, especially in regenerative medicine and disease treatment.